Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED),Diabetes & Metabolism

当前位置： X-MOL 学术 › Diabetes Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)
Diabetes & Metabolism ( IF 7.2 ) Pub Date : 2023-04-26 , DOI: 10.1016/j.diabet.2023.101447
Atsushi Tanaka ₁ , Yosuke Okada ₂ , Keiichi Torimoto ₂ , Nozomu Kamei ₃ , Hiroyuki Hirai ₄ , Teruyuki Kono ₅ , Kazuhiro Sugimoto ₆ , Hiroki Teragawa ₇ , Isao Taguchi ₈ , Tatsuya Maruhashi ₉ , Satomi Sonoda ₁₀ , Akira Kurozumi ₁₀ , Saori Inagaki ₁₁ , Chikage Oshita ₁₂ , Itaru Hisauchi ₁₃ , Kanae Takahashi ₁₄ , Yukihito Higashi ₁₅ , Michio Shimabukuro ₁₆ , Koichi Node ₁₇ ,

Affiliation

Department of Cardiovascular Medicine, Saga University, Saga, Japan.
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan.
Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Japan.
Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Department of Biostatistics, Hyogo Medical University, Nishinomiya, Japan.
Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
Department of Cardiovascular Medicine, Saga University, Saga, Japan.